This phase 2 trial is evaluating the effectiveness of using an immunotherapy (talimogene laherparepvec) in combination with a targeted therapy (pembrolizumab) to treat patients with melanoma, who have had disease progression while on immune checkpoint inhibitors (anti-PD-1 therapy).
This trial is treating patients with Melanoma.
This is a systemic therapy.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy
Commercial Sponsor
AMGEN
Summary
Patients eligible to participate in this trial will receive injections of talimogene laherparepvec directly into the lesions on Day 1 of the trial and every 3 weeks after the first injection. Pembrolizumab will be administered intravenously every 3 weeks.
Recruiting Hospitals Read More